Equities research analysts at StockNews.com started coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research note issued to investors on Thursday. The brokerage set a "sell" rating on the stock.
Advaxis Stock Performance
ADXS opened at $3.03 on Thursday. The firm has a market cap of $5.50 million, a P/E ratio of -0.45 and a beta of 2.20. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $51.60.
Get Advaxis alerts:About Advaxis
(Get Rating)
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.See Also
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- 3 High Margin Chipmakers Bound to Recover
- 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.